Why Biofrontera Inc.’s dual database locks mark a critical step toward validated clinical and regulatory data

By on    Pharma & Biotech  

Why Biofrontera Inc.’s dual database locks mark a critical step toward validated clinical and regulatory data

Biofrontera Inc. has confirmed that databases for two of its clinical studies have been formally locked, a procedural milestone that signals the completion of data collection and validation and the transition into final statistical analysis. Although database locks rarely attract the same level of attention as topline efficacy readouts, they represent one of the most […]

Ventyx to give Lilly an oral inflammation pipeline—what’s the real upside?

By on    Pharma & Biotech  

Ventyx to give Lilly an oral inflammation pipeline—what’s the real upside?

Eli Lilly and Company has announced plans to acquire Ventyx Biosciences Inc. in an all-cash transaction valued at approximately $1.2 billion, securing a portfolio of clinical-stage oral small molecule therapeutics focused on chronic inflammatory-mediated diseases. The deal includes NLRP3 inhibitors such as VTX2735 and VTX3232, alongside two Phase 2 programs for inflammatory bowel disease. The […]

Can early access programs reshape the approval arc for rare disease gene therapies?

By on    Features & Analysis  

Can early access programs reshape the approval arc for rare disease gene therapies?

GenSight Biologics S.A.’s early access rollout of GS010/LUMEVOQ in France and Israel has drawn new attention to how regulators are quietly repurposing compassionate use frameworks into strategic regulatory sandboxes for advanced therapies. As rare disease gene therapies edge closer to commercial viability, a patchwork of early access programs across key jurisdictions is beginning to influence […]

1 2 3 4